☆ 4.8 Article

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

NATURE MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Gastroenterology & Hepatology

Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer

Eiji Oki et al.

Summary: Numerous clinical studies have been conducted on adjuvant therapy, with the combination of 5-fluorouracil and oxaliplatin established as the standard treatment for Stage III and high-risk Stage II patients. Biologics like bevacizumab and antiepidermal growth factor receptor antibodies have not shown additional survival benefits. The ultimate goal is to accurately predict the risk of recurrence in colon cancer patients and prevent recurrence.

ANNALS OF GASTROENTEROLOGICAL SURGERY (2022)

添加到收藏夹

Article Medicine, General & Internal

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

Jeanne Tie et al.

Summary: This study found that using ctDNA results to guide treatment decisions for stage II colon cancer reduced the use of adjuvant chemotherapy without compromising recurrence-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Oncology

Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors

Pashtoon M. Kasi et al.

Summary: The use of circulating tumor DNA (ctDNA) for detecting molecular residual disease (MRD) has the potential to significantly impact cancer management by enabling earlier detection of cancer recurrence. Numerous studies have shown that ctDNA-based MRD detection predicts recurrence with high sensitivity and specificity, often preceding standard imaging by up to 12 months. Recent developments include the use of ctDNA testing to enroll high-risk MRD-positive patients into clinical trials, leading to improved statistical power and potential reductions in trial duration. The use of ctDNA dynamics or clearance as a surrogate endpoint is also gaining support, offering further potential for shorter trial durations.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹

Letter Oncology

Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA)

Emily A. Verbus et al.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer

Hiroya Taniguchi et al.

Summary: Adaptive platform trials like CIRCULATE-Japan aim to evaluate the clinical benefits of ctDNA analysis and refine precision adjuvant therapy for resectable colorectal cancer. The trials include GALAXY, VEGA, and ALTAIR studies which focus on both de-escalation and escalation for ctDNA-negative and -positive patients respectively.

CANCER SCIENCE (2021)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

T. Yoshino et al.

Summary: The ESMO 2020 guidelines for localised colon cancer were adapted to account for ethnic differences in Asian patients during a special virtual meeting convened by ESMO and JSMO in March 2021. These guidelines represent the consensus opinions of experts from various oncological societies in Asia, and the voting was based on scientific evidence.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Thomas Powles et al.

Summary: The study found that using ctDNA testing to identify high-risk patients for relapse after surgery may improve treatment outcomes, with atezolizumab showing potential benefits in this patient population.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer

Pashtoon Murtaza Kasi et al.

Summary: This study investigates the clinical utility of ctDNA in optimizing adjuvant chemotherapy for surgically resected CRC patients and detecting early disease progression. Bespoke ctDNA testing impact on adjuvant treatment decisions and monitoring CRC recurrence rates are the primary endpoints of the study.

BMJ OPEN (2021)

添加到收藏夹

Article Oncology

The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA

Tenna V. Henriksen et al.

MOLECULAR ONCOLOGY (2020)

添加到收藏夹

Article Oncology

A new prognostic and predictive tool for shared decision making in stage III colon cancer

Alberto F. Sobrero et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Review Oncology

Precision medicine for gastrointestinal cancer: Recent progress and future perspective

Tasuku Matsuoka et al.

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence

Raoul Charles Coombes et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer

Yuxuan Wang et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer

Thomas Reinert et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

Jeanne Tie et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Adjuvant chemotherapy for resected colorectal cancer metastases: literature review and meta-analysis

Giovanni Brandi et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2016)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases

Emily Khoo et al.

HPB (2016)

添加到收藏夹

Article Oncology

Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features

Erin S. O'Connor et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Editorial Material Oncology

Path Toward Prognostication and Prediction: An Evolving Matrix

Al B. Benson et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Oncology

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07

J. Philip Kuebler et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

添加到收藏夹

Article Medicine, General & Internal

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer

T Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.